Share-based Payment Arrangement, Expense of Inmune Bio, Inc. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Inmune Bio, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • Inmune Bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,984,000, a 74% increase year-over-year.
  • Inmune Bio, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,779,000, a 76% decline from 2023.
  • Inmune Bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,368,000, a 3.1% increase from 2022.
  • Inmune Bio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,149,000, a 49% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Inmune Bio, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,984,000 +$1,265,000 +74% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $1,534,000 -$816,000 -35% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $2,076,000 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q3 2024 $1,719,000 -$170,000 -9% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025 2025 Q3
Q2 2024 $2,350,000 +$487,000 +26% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q4 2023 $7,368,000 $1,916,000 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $1,889,000 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q2 2023 $1,863,000 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $1,700,000 +$200,000 +13% 01 Jan 2023 31 Mar 2023 10-Q 03 May 2023 2023 Q1
Q1 2022 $1,500,000 +$600,000 +67% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q1 2021 $900,000 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $2,755,000 01 Dec 2020 31 Dec 2020 10-K 03 Mar 2022 2021 FY

Inmune Bio, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,779,000 -$5,589,000 -76% 01 Jan 2024 31 Dec 2024 10-Q 08 May 2025 2025 Q1
2023 $7,368,000 +$219,000 +3.1% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $7,149,000 +$2,353,000 +49% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $4,796,000 01 Jan 2021 31 Dec 2021 10-K 02 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.